Paysign remains a buy, supported by strong performance in both Plasma Centers and hypergrowth in Patient Affordability. PAYS's Plasma Center segment holds a 50% market share, adding 115 new centers in FY25, despite revenue per center declining due to plasma surplus. That surplus can disappear, and the Plasma segment can benefit from the BECS, generating high-margin SaaS subscription revenue.

Paysign (NASDAQ: PAYS) reported fourth-quarter and full-year 2025 results that management said showed "continued strength and exceptional growth" across key metrics, driven primarily by rapid expansion in its patient affordability platform and improving operating leverage. Full-year 2025 results and margin improvement For full-year 2025, the company said revenue increased 40.5% to $82.0 million. Net income rose

Paysign posted Q4 earnings that were in line with Wall Street's target and sales that beat expectations. The company's forward guidance is spurring huge gains for the stock.

Paysign, Inc. (PAYS) Q4 2025 Earnings Call Transcript

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results.

Paysign, Inc. (NASDAQ: PAYS - Get Free Report) has been assigned an average rating of "Moderate Buy" from the five research firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price

Marqeta (NASDAQ: MQ - Get Free Report) and Paysign (NASDAQ: PAYS - Get Free Report) are both small-cap business services companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, institutional ownership and dividends. Profitability This table compares Marqeta and Paysign's net

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign to Host Fourth Quarter and Full Year 2025 Earnings Call.

Shares of Paysign, Inc. (NASDAQ: PAYS - Get Free Report) have received an average rating of "Moderate Buy" from the five ratings firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year target

Freightos (NASDAQ: CRGO - Get Free Report) and Paysign (NASDAQ: PAYS - Get Free Report) are both small-cap business services companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends. Profitability This table compares Freightos and Paysign's net